rituximab + fludarabine + cyclophosphamide

Rituximab + fludarabine + cyclophosphamide (RFC) is a combination chemoimmunotherapy regimen used primarily in the treatment of B-cell malignancies, such as follicular lymphoma and chronic lymphocytic leukemia. The regimen consists of **rituximab**, a chimeric monoclonal antibody that targets the CD20 antigen on B-lymphocytes; **fludarabine**, a purine nucleoside analog that interferes with DNA synthesis; and **cyclophosphamide**, an alkylating agent that cross-links DNA. This specific combination was evaluated by the **Asociacion Espanola de Hematologia y Hemoterapia (AEHH)** in the Phase 4 LNHF-03 clinical trial as a first-line treatment for follicular lymphoma, followed by rituximab maintenance. While the regimen demonstrated high efficacy with significant complete remission rates, it is also associated with notable hematological toxicity.

Other names

Rituximab-Fludarabine-CyclophosphamideRFC regimen